Celgene Corporation Release: Clinical Study In The Journal Of Clinical Oncology Reports Patients With Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID With Standard R-CHOP Achieved 98% Overall Response Rate And 80% Complete Response Rate

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that results of a study evaluating the combination of REVLIMID® (lenalidomide) with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) in untreated diffuse large b-cell lymphoma (DLBCL) were published online ahead of print in the Journal of Clinical Oncology.

Help employers find you! Check out all the jobs and post your resume.